Search

Headquarters

Contact Us

  • (+01) 512 835 8026
  • info@myriadrbm.com
  • 3300 Duval Road
    Austin, TX 78759
    USA
  • Mon to Fri - 8:50am to 5:00pm

Ready to order?

Great! Every order starts with a quote.

Get Started

  • (+01) 512 835 8026
  • info@myriadrbm.com
Get a Quote Contact | FAQ's | Blog
Myriad RBM Myriad RBM

Innovative Biomarker Solutions

Toggle menu

Skip to content
  • About Us
    • About Myriad RBM

      Myriad RBM’s CLIA certified biomarker testing laboratory, is located in Austin, TX. Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. (MYGN), a leading molecular diagnostic company based in Salt Lake City, Utah which develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests.
    • About Myriad RBM

      • About Us
      • Management
      • Quality Policy
      • Employment
      • Partners
      • Sales Team
      • Certifications
    • Newsroom

      • Press
      • Company Newsletters
      • Conferences
      • Abstracts + Papers
      • Sign Up for Our Newsletter
      • Blog
    • Data Quality

      • Overview
      • Myriad RBM Technology
  • Biomarker Solutions
    • Solutions

      • Overview
      • Assay Change Log

      CustomMAP

      If a smaller, more focused panel of analytes is required, we can build a Custom MAP to meet your needs.

      Learn More »

      TruCulture Spike

    • Multiplexed Immunoassays

      • Full Biomarker Menu
      • DiscoveryMAP® v. 4.0
      • ExplorerMAP™ v. 1.0
      • HumanMAP® v. 2.0
      • CardiovascularMAP® v. 3.0
      • AngiogenesisMAP® v. 1.0
      • InflammationMAP® v. 1.1
      • ImmunoMAP® v. 1.0
      • MetabolicMAP® v. 1.0
      • KidneyMAP®
      • CytokineMAP A
      • CytokineMAP B
      • SARS-CoV-2/COVID-19 Research
      • Cytokine Storm Testing for SARS-CoV-2/COVID-19 Research
      • SARS-CoV-2 Multiplex Serology
      Webinar Registration
    • TruCulture

      Whole Blood Collection and Culture System

      Learn More »
      Quanterix simoa

      Ultrasensitive immunoassays manufactured by Myriad RBM and based on Quanterix’s Simoa technology.

      Learn More »
  • Resources + Support
    • Resources

      • Bibliography
      • White Papers
      • Application Notes
      • Events
      • Webinars
      • Blog
      • COVID-19/SARS-CoV-2 Research Tools
    • Support

      • Client Services
      • Request a Biomarker
      • Speak to a Scientist
  • How to Order
    • Ordering Information

      • How to Order
      • Request a quote
      • Acceptable Samples
      • Frequently Asked Questions
    • Request Information

      • Contact Client Services
      • Request a Biomarker
      • Speak to a Scientist
    • Ready to Order?

      Great!

      Every order starts with a quote.

      Get Started

  •  

Author Archives: huckster

10 Mar 2015

Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa™ Platform

March 10, 2015
huckster
Press
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com  ...
Read More
20 Jan 2015

Myriad RBM Joins Institut Pasteur in the Global Fight against Tuberculosis

January 20, 2015
huckster
Press
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com  ...
Read More
20 Mar 2014

Institut Pasteur and Myriad RBM Publish Initial Results from Landmark Study of Immune Response

March 20, 2014
huckster
Press
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com Institut Past...
Read More
19 Jun 2013

DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration

June 19, 2013
huckster
Press
DaVita Contact: Bianca Violante (303) 876-6614 bianca.violante@davita.com Investor Contact: Jim Gustafson (310) 536-2585 jim.gustafson@davita...
Read More
10 Dec 2012

Myriad Announces Diabetes Collaboration with Sanofi – Press Release

December 10, 2012
huckster
Press
Myriad Contacts Investor Relations: Jim Evans, Chief Financial Officer (801) 584-1143 investors@myriad.com Myriad RBM: Chris Martin, Director o...
Read More
9 May 2012

Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

May 9, 2012
huckster
Press
New panel expands Myriad RBM's cancer-related drug and companion diagnostic discovery service offering. Salt Lake City, UT (PRWEB) May 09, 2012...
Read More
28 Apr 2011

Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine

April 28, 2011
huckster
Press
Acquisition Expands Myriad's Leadership Position in Companion Diagnostics SALT LAKE CITY and AUSTIN, Texas, April 27, 2011 (GLOBE NEWSWIRE) -- Myri...
Read More

Categories

  • Biomarkers (4)
  • Blog (134)
    • Autoimmune and Arthritis (10)
    • Cancer (28)
    • Cardiac (9)
    • Cytokines and Chemokines (20)
    • Diabetes (7)
    • Gastrointestinal (1)
    • Inflammation (42)
    • Neuroscience and Neurological (33)
    • News From the Lab (1)
    • Renal Function and Toxicity (8)
    • Technology- Multi-Analyte Profile (1)
    • TruCulture (2)
  • COVID-19 (1)
  • Press (37)
  • Utilized Myriad RBM's Services (43)

ABOUT MYRIAD RBM

Overview
Management
Quality Policy
Employment
Partners
Sales Team
Certifications

MAPs

Full Biomarker Menu
DiscoveryMAP® v. 3.3
ExplorerMAP™ v. 1.0
HumanMAP® v. 2.0
CardiovascularMAP® v. 3.0
AngiogenesisMAP® v. 1.0
InflammationMAP® v. 1.0
ImmunoMAP® v. 1.0
NeuroMAP™ v. 1.0
MetabolicMAP® v. 1.0
KidneyMAP®
CytokineMAP A
CytokineMAP B

RESOURCES

Bibliography
White Papers
Events
Webinars
Blog

SUPPORT

Customer Support
Speak to a Scientist
Assay Change Log
Request a Biomarker
FAQs

SOLUTIONS

Results Processing
Assay Development
Quality Control
Project Management

SERVICES

Multiplexed Assay Services
Ultrasensitive Assays
TruCulture

  • Jobs
  • Terms of Use
  • Privacy Practice
  • Analytes Listing
Copyright © 2021 Myriad RBM. All rights reserved. Myriad does not sell your personal information